Literature DB >> 10338492

Role of Pneumolysin's complement-activating activity during pneumococcal bacteremia in cirrhotic rats.

R B Alcantara1, L C Preheim, M J Gentry.   

Abstract

We investigated the role of pneumolysin's complement-activating activity during Streptococcus pneumoniae bacteremia in a hypocomplementemic, cirrhotic host. Isogenic mutant pneumococcal strains, in which pneumolysin was expressed from a plasmid, were used. These strains included H+C+, expressing wild-type pneumolysin with both cytolytic and complement-activating activity; PLY-, carrying the plasmid without the pneumolysin gene; and, H+C-, expressing pneumolysin with cytolytic activity only. In control rats, intravenous infection with 2.0 x 10(7) CFU of H+C+ per ml of blood resulted in a decrease in bacteremia of 3.5 log units by 18 h postinfection and 55% mortality. By contrast, cirrhotic rats infected similarly with the H+C+ strain demonstrated a 0.2-log-unit increase in bacteremia by 18 h postinfection and 100% mortality. Both control and cirrhotic rats cleared the PLY- strain more effectively from their bloodstreams by 18 h postinfection (6.2 and 5. 6 log unit decreases, respectively). Infection with the PLY- strain also resulted in low mortality (0 and 14%, respectively) for control and cirrhotic rats. When infected with the H+C- strain (without complement-activating activity), both groups cleared the organism from their bloodstreams nearly as well as they did the PLY- strain. Furthermore, the mortality rate for control and cirrhotic rats was identical after infection with the H+C- strain. These studies suggest that pneumolysin production contributes to decreased pneumococcal clearance from the bloodstream and higher mortality in both control and cirrhotic rats. However, pneumolysin's complement-activating activity may uniquely enhance pneumococcal virulence in the hypocomplementemic, cirrhotic host.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10338492      PMCID: PMC96593          DOI: 10.1128/IAI.67.6.2862-2866.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

Review 1.  Biological properties of pneumolysin.

Authors:  T J Mitchell; P W Andrew
Journal:  Microb Drug Resist       Date:  1997       Impact factor: 3.431

2.  Activation of human complement by the pneumococcal toxin pneumolysin.

Authors:  J C Paton; B Rowan-Kelly; A Ferrante
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

Review 3.  Pneumolysin: a multifunctional pneumococcal virulence factor.

Authors:  J B Rubins; E N Janoff
Journal:  J Lab Clin Med       Date:  1998-01

4.  Pneumococcal bacteremia--no change in mortality in 30 years: analysis of 104 cases and review of the literature.

Authors:  M R Kramer; B Rudensky; I Hadas-Halperin; M Isacsohn; E Melzer
Journal:  Isr J Med Sci       Date:  1987-03

Review 5.  Pneumococcal virulence factors and host immune responses to them.

Authors:  D A Watson; D M Musher; J Verhoef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-06       Impact factor: 3.267

Review 6.  Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines.

Authors:  E AlonsoDeVelasco; A F Verheul; J Verhoef; H Snippe
Journal:  Microbiol Rev       Date:  1995-12

7.  Growth and virulence of a complement-activation-negative mutant of Streptococcus pneumoniae in the rabbit cornea.

Authors:  M K Johnson; M C Callegan; L S Engel; R J O'Callaghan; J M Hill; J A Hobden; G J Boulnois; P W Andrew; T J Mitchell
Journal:  Curr Eye Res       Date:  1995-04       Impact factor: 2.424

8.  Confirmation of the role of pneumolysin in ocular infections with Streptococcus pneumoniae.

Authors:  M K Johnson; J A Hobden; R J O'Callaghan; J M Hill
Journal:  Curr Eye Res       Date:  1992-12       Impact factor: 2.424

9.  The critical role of complement in experimental pneumococcal sepsis.

Authors:  S W Hosea; E J Brown; M M Frank
Journal:  J Infect Dis       Date:  1980-12       Impact factor: 5.226

Review 10.  The role of antibody and complement in the reticuloendothelial clearance of pneumococci from the bloodstream.

Authors:  E J Brown; S W Hosea; M M Frank
Journal:  Rev Infect Dis       Date:  1983 Sep-Oct
View more
  13 in total

1.  Pneumolysin-induced complement depletion during experimental pneumococcal bacteremia.

Authors:  R B Alcantara; L C Preheim; M J Gentry-Nielsen
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

Review 2.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

Review 3.  Alcohol abuse and Streptococcus pneumoniae infections: consideration of virulence factors and impaired immune responses.

Authors:  Minny Bhatty; Stephen B Pruett; Edwin Swiatlo; Bindu Nanduri
Journal:  Alcohol       Date:  2011-09       Impact factor: 2.405

4.  Immunization with genetic toxoids of the Arcanobacterium pyogenes cholesterol-dependent cytolysin, pyolysin, protects mice against infection.

Authors:  B Helen Jost; Hien T Trinh; J Glenn Songer; Stephen J Billington
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

5.  Decreased virulence of a pneumolysin-deficient strain of Streptococcus pneumoniae in murine meningitis.

Authors:  Andreas Wellmer; Gregor Zysk; Joachim Gerber; Tammo Kunst; Matthias Von Mering; Stefanie Bunkowski; Helmut Eiffert; Roland Nau
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

6.  Innate immune defense against pneumococcal pneumonia requires pulmonary complement component C3.

Authors:  Alison R Kerr; Gavin K Paterson; Alan Riboldi-Tunnicliffe; Tim J Mitchell
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

Review 7.  Streptococcus pneumoniae: Invasion and Inflammation.

Authors:  Allister J Loughran; Carlos J Orihuela; Elaine I Tuomanen
Journal:  Microbiol Spectr       Date:  2019-03

Review 8.  Drug treatment of pneumococcal pneumonia in the elderly.

Authors:  Sridhar Neralla; Keith C Meyer
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  Influence of neutropenia on the course of serotype 8 pneumococcal pneumonia in mice.

Authors:  Matthew Marks; Tamika Burns; Maria Abadi; Beza Seyoum; Justin Thornton; Elaine Tuomanen; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-02-12       Impact factor: 3.441

Review 10.  Animal models of Streptococcus pneumoniae disease.

Authors:  Damiana Chiavolini; Gianni Pozzi; Susanna Ricci
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.